Disruptive medical device platform for your brand success !
Cryonove Pharma offers innovative medical devices for indications in dermatology and dermocosmetics using disruptive technology.
After several years of research and development, Cryonove Pharma has perfected a scientific platform based on a technology that can modulate the behavior of skin cells with optimum tolerance.
This technology is disruptive, offering for the first time the possibility of interacting with cell viability and synthesis, through the creation of oscillatory thermal shocks (ultra-fast, repeated thermal shocks). The results (tolerance and performance) validated in several clinical studies are exceptional and far superior to those of cosmetic products.
Our scientific platform includes specific investigation and measurement tools, dedicated in-vitro (2D and 3D) and ex-vivo methodologies and technical resources. Several indications have been explored and the company now has its first medical devices (prototypes, finished devices, technical files and CE marking) and production tools.
The technology developed by Cryonove Pharma is based on the principle of creating oscillatory thermal shocks (ultra-fast, repeated thermal shocks) on the skin surface at positive temperatures. These thermol shocks are obtained through thermal exchanges whose characteristics (number, kinetics, flow rate, minimum temperature reached) are specific to the expected cellular response, and therefore to the indication under study. The creation of these oscillatory heat exchanges at positive temperatures and the means by which they are achieved have been the subject of a considerable number of experiments. The validated technology benefits from numerous barriers to entry and is protected by several patents.
The resulting effect enables certain cell populations to be targeted more specifically, while preserving other cells, thus generating a cyto-selective action. This feature considerably improves treatment tolerance and efficacy.
A first application of this disruptive technology is the treatment of solar and senile lentigos. These brown spots, more commonly known as age spots, appear over the years and are the result of a disturbance in melanin synthesis by melanocytes, the cells located in the epidermis. The technology we have developed enables us to specifically target the melanocytes responsible for hyperpigmentation and definitively treat brown spots with no side effects on the skin.
Dozens of studies (in-vitro, ex-vivo) have been carried out since 2016 in our laboratory in Besançon (France). These conclusive preliminary studies were followed by several POC (proof of concept) clinical studies. Today, clinical proof of exceptional performance and tolerance in two initial indications has been definitively acquired (solar and senile lentigos, post-inflammatory hyperpigmentation). Studies on other indications unsatisfied by the current offering in high-potential markets are underway and will soon be available.
Cryonove Pharma possesses and masters unique know-how in the automated application of oscillatory thermal shocks at positive temperatures on the skin. Cryonove Pharma is the exclusive owner of several worldwide patents validated for their freedom of use in various dermatological and dermocosmetic indications. Other patents are in the process of being registered. Numerous ad hoc research and development tools have been developed by the company to meet the challenges of the technology under study, which combines mechanical, thermal and flow dynamic properties. Our aim is to enable your brands to benefit from this unique know-how for innovative dermatological and dermocosmetic devices.
Cryonove pharma has implemented a quality management system since its creation. Its medical devices can be brought to market rapidly. The company has already obtained CE marking under the new MDR for one of its medical devices (treatment of brown spots on the hands), with a broad scope that will enable it to more easily complete the list of devices that can be marketed in Europe in dermatology and dermocosmetics with its positive-temperature thermal oscillatory shock technology.
Cryonove Pharma is a research and development SAS founded in 2016 with capital of 448,643 euros. It has raised several rounds of financing. Its mission is to develop disruptive medical devices based on positive-temperature oscillatory thermal shock technology for high-potential dermatology and dermocosmetic indications and offer them to partners for their brands. Cryonove Pharma’s ecosystem has been built to ensure the responsiveness, flexibility and security of a research company in the face of hazards and opportunities. Cryonove Pharma has surrounded itself with the skills of recognized partners, each in their own field of excellence, so that it can concentrate solely on its mission and expertise in oscillatory thermal shock at positive temperatures.
As CEO of Cryonove Pharma, I am responsible for the company’s development and strategy. After some twenty years in sales, marketing and management positions in various multinational companies, I have to my credit a first entrepreneurial success from 1998 to 2008 with the sale to the Omega Pharma group of class IIa medical devices that have become market leaders. Co-founder with Jean-Christophe Anton of Cryonove Pharma, we develop disruptive dermatological and dermocosmetic medical devices for third-party brands, based on cutting-edge technology.
Scientific Director, responsible for R&D, quality and regulatory operations, I am co-founder of Cryonove Pharma. I have built my career within pharmaceutical companies and start-ups in the field of research and development in France, Germany and the US. I also set up a consulting company in pharmaceuticals, nutraceuticals and cosmetics, and gained operational experience for Pierre Fabre Laboratories in France, during which I launched several products worldwide. I hold a Doctor of Pharmacy degree, DESS (industry option), and also have expertise in patent law (CEIPI).
Cryonove Pharma bénéficie des compétences de sociétés reconnues chacune dans leur domaine d’excellence dont Clayens pour l’industrialisation de son dispositif médical, Coster pour le développement de sa bonbonne, FCA pour l’assemblage de la bonbonne, CATS pour le PCB, NAMSA pour la partie réglementaire, BPI pour son accompagnement financier…
A single application of a few seconds every week for six weeks and the brown spot disappears in six weeks. To find out more, contact us
*After CE mark planned in 2026
A single application of a few seconds every week for six weeks and the brown spot disappears in six weeks. To find out more, contact us
*After CE mark planned in 2026
De premiers résultats sur d’autres indications insatisfaites par l’offre actuelle sur des marchés à très fort potentiel seront bientôt disponibles pour une présentation (Rides, cicatrices…)
We invite you to contact us if you would like to find out more about our technology and medical devices.
De premiers résultats sur d’autres indications insatisfaites par l’offre actuelle sur des marché à très fort potentiel seront bientôt disponibles pour une présentation.
Our answer within 72H
our contact details
Paris France
d.marin@cryonovepharma.com
Mobile : +33(6) 09 02 13 67
